SAGE Stock Summary and Trading Ideas (Sage Therapeutics | NASDAQ:SAGE)

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics trades on the NASDAQ stock market under the symbol SAGE.

As of December 12, 2024, SAGE stock price declined to $5.67 with 1,566,680 million shares trading.

SAGE has a beta of 2.59, meaning it tends to be more sensitive to market movements. SAGE has a correlation of 0.25 to the broad based SPY ETF.

SAGE has a market cap of $346.85 million. This is considered a Small Cap stock.

Last quarter Sage Therapeutics reported $12 million in Revenue and -$1.53 earnings per share. This beat revenue expectation by $1 million and met earnings estimates .

In the last 3 years, SAGE traded as high as $59.99 and as low as $4.62.

The top ETF exchange traded funds that SAGE belongs to (by Net Assets): VTI, IWM, XBI, VXF, VB.

SAGE has underperformed the market in the last year with a return of -71.7%, while the SPY ETF gained +32.3%. In the last 3 month period, SAGE fell short of the market, returning -24.3%, while SPY returned +9.3%. However, in the most recent 2 weeks SAGE has outperformed the stock market by returning +2.2%, while SPY returned +0.9%.

SAGE support price is $5.62 and resistance is $6.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SAGE shares will trade within this expected range on the day.